Lexicon Pharmaceuticals LXRX Proceeds From Issuance Of Convertible Preferred Stock

Proceeds From Issuance Of Convertible Preferred Stock at other companies

KKR & Co.KKR

$0-100%

Lexicon PharmaceuticalsLXRX

$26.55M—

QuantumScape Corporation QS

$44.12M—

Maze Therapeutics, Inc. Common StockMAZE

$17.7M—

Evolution Metals & Technologies Corp. EMAT

$5.55M—

Lexicon PharmaceuticalsLXRX

$26.55M—

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$1.02B+273%

Enterprise value$1.01B+219%

P/S14.6×+5.9×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's proceeds from issuance of convertible preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's proceeds from issuance of convertible preferred stock?: Lexicon Pharmaceuticals (LXRX) reported proceeds from issuance of convertible preferred stock of $26.55M in Q1 2026.